ASIA-PACIFIC Education
Expert Perspectives: Highlights on HCV from EASL 2017
APASL 2017 Conference - Shanghai, China
Expert Perspectives: Highlights on HCV from AASLD 2016
Expert Perspectives: Best of HCV - 2016 Spring Update
APASL 2016 Conference - Tokyo, Japan
Adrian Di Bisceglie, MD
Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences
Watch
17:26 min
Geoffrey McCaughan, MD
Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences
Watch
17:38 min
E. Estrabaud and P. Marcellin
Supported by: AbbVie, Bristol-Myers Squibb, and Gilead Sciences
Watch
17:22 min
The 4th ASEAN Perspective in Liver Diseases (Thailand)
Expert Perspectives: Best of HCV – 2015 Year End Update
Review of the WHO Guidelines for the Screening, Care, and
Treatment of Persons with HCV
2015 Singapore Hepatitis Conference Coverage
Expert Perspectives: Best of HCV from EASL 2015
2015 APASL Conference Coverage - Istanbul, Turkey
2014 Education
APASL STC: Pakistan 2014
Best of HCV from AASLD 2014
2014 Singapore Hepatitis Conference Coverage
- Introduction: Treatment of Hepatitis C in Asia: The Issues Seng Gee Lim, Singapore Watch
- Hepatitis C Diseases Burden in Asia: Limitations and Prospects Pei-Jer Chen, Taiwan Watch
- Management of Adverse Events Wei Lai, China Watch
- Predictors of Response and Stopping Rules Henry Chan, China Watch
- Do we still Need Interferon for the New DAA's Teerha Piratvisuth, Thailand Watch
- The Promise of Interferon Free Therapy Raj Reddy, USA Watch
- New Therapeutic Strategies Stefan Zeuzem, Germany Watch
- Differences in Approaches - West vs. East Raj Reddy, USA Watch
- Genotype 2 vs 3 Samir Shah, India Watch
- Genotype 6 Qin Ning, China Watch
- Treat now / Treat Later R. Gish & M. Schiffman, USA Watch
- Treatment Failures Stefan Zeuzem, Germany Watch
- Cirrhotic Patients Robert Gish, USA Watch
- Transplant Patients Mitchell Shiffman, USA Watch
- Co-infected Patients Jai Horng Kao, Taiwan Watch
- Understanding Healthcare Systems in Asia Dan Yock Young, Singapore Watch
- Access to New DAAs in Asia Samir Shah, India Watch
- Cost Effectiveness Models for HCV Therapy Dan Yock Young, Singapore Watch
- Conclusion and Algorithm for HCV Therapy in Asia Seng Gee Lim, Singapore Watch
2014 APASL Conference Coverage - Brisbane, Australia
- Triple Therapy in 2013 and beyond in Asia Tawesak Tanwandee, MD Watch
- Drug Resistance and Treatment Failure in Asia Masashi Mizokami, MD Watch
- Hepatitis C - Current Treatments: What Can We Offer Patients Now? Domini Ray-Chaudhuri, MD Watch
- Funding, access and infrastructure for new HCV therapies across Asia Pacific Charles Gore, President, WHA Watch
- Public Health strategies to reduce liver disease in the Asia Pacific Region Charles Gore, President, WHA Watch
- Optimizing triple therapy, and IFN/RBV free regimens Kazuaki Chayama Watch
- Direct Acting Antivirals for HCV GT-1 State of Play in 2014 Ed Gane Watch
- Hepatitis C virus lifecycle: What are the best drug targets? Michael Beard Watch
- Hepatitis C Direct Acting Antivirals for Genotypes 2/3: State of Play 2014 Catherine Stedman Watch
- Host genomics and HCV treatment response: IL-28B and beyond Alex Thompson Watch
2013 APASL Conference Coverage - Singapore
- Current Therapy and Changing Landscape in the Near Future Ed Gane Watch
- How to Use Triple Therapy for Genotype 1 HCV Infection: Treatment-naÏve Patients Chun-Jen Liu, MD,PhD Watch
- Treatment Experience Patients Rafael Esteban Watch
- How to use Triple Therapy for HCV-1 Pre-Treatment Predictors - What to Test? Alex Thompson, MBBS, PhD, FRACP Watch
- Chronic Hepatitis C - Whom Not to Treat Peter Ferenci Watch
- Which Patients to Treat and Which to Keep? Patrick Marcellin Watch
- Cirrhosis: Real Life Versus Clinical Trial Marc Bourliere, MD Watch
- Future Strategies: Direct Acting Antivirals Heiner Wedemeyer, MD Watch
- Special Populations, Patients with Renal Disease, Post Renal Transplant, and Co-Infected Patients Samuel S. Lee, MD Watch
- HCV Triple Therapy: Management of Side Effects Samuel S. Lee, MD Watch
- Drug Interactions and DAA's Jacob George, MD Watch